#None #Cambridge #biotechnology #Harbour BioMed #Luisa Salter-Cid

Harbour BioMed Welcomes Dr. Luisa Salter-Cid as New Scientific Advisor

Harbour BioMed, a leading global company in biopharmaceuticals, has recently made a significant addition to its team by appointing Dr. Luisa Salter-Cid as a Scientific Advisor. This announcement, made on June 10, 2026, marks an important step in the company’s mission to innovate and develop novel therapies in the fields of immunology and oncology.

Dr. Luisa Salter-Cid: A Proven Leader in Biotech

Dr. Salter-Cid comes with an impressive background, having accumulated over 20 years of rich expertise in both the biotechnology and pharmaceutical sectors. Her previous roles include high-profile positions at notable companies such as Flagship Pioneering, Bristol Myers Squibb, and Gossamer Bio. This wealth of experience in managing and developing immunology and immuno-oncology projects makes her an invaluable asset for Harbour BioMed.

A Track Record of Success

Throughout her career, Dr. Salter-Cid has demonstrated her ability to take scientific concepts and successfully translate them into viable clinical assets. At Flagship Pioneering, where she served as Chief Scientific Officer of Pioneering Medicines, she was at the forefront of developing a portfolio that drew breakthroughs from a wide array of scientific platforms. Her previous experience at Bristol Myers Squibb included leading the Immunology division, where she played a critical role in advancing more than 20 compounds into clinical development.

Dr. Salter-Cid's role at Harbour BioMed is expected to leverage her extensive knowledge and strategic insights to bolster the company’s initiatives and research into novel therapeutic options. Her capabilities as a thought leader and strategist are expected to significantly enhance Harbour BioMed's efforts to meet global medical needs.

Strategic Vision for the Future

Upon her appointment, Dr. Salter-Cid expressed her excitement about joining the team, highlighting Harbour BioMed's innovative use of its proprietary Harbour Mice technology and its commitment to creating effective therapeutics. She aims to contribute to the company’s strategic vision, ensuring new life-saving medicines reach patients in need more swiftly.

Dr. Jingsong Wang, the Founder, Chairman, and CEO of Harbour BioMed, shared his enthusiasm about having Dr. Salter-Cid on board, noting her deep expertise in immunology. He emphasized the need for innovative approaches in drug development and believes Dr. Salter-Cid's contributions will be instrumental in navigating those complex challenges.

A Bright Future Ahead

Harbour BioMed is known for its robust pipeline and continued investment in research and development. With Dr. Salter-Cid leading scientific advisory efforts, the company is poised to strengthen its position in the biopharmaceutical arena, focusing on creating therapeutic solutions that address underserved patient populations.

As Harbour BioMed embarks on this new chapter, with Dr. Salter-Cid as a guiding force, the expectations are high for the advancements the company will achieve in the biopharmaceutical landscape. The integration of her insights into their scientific strategies is anticipated not only to foster innovation but also to speed up the journey from lab to clinical application.

By consistently pushing the boundaries of science and medicine, Harbour BioMed continues to illustrate its commitment to addressing the evolving needs of the healthcare landscape. As they build on their existing technology and pipeline, all eyes will be on how Dr. Salter-Cid’s appointments will influence future breakthroughs and collaborations.

For more information about Harbour BioMed and their work, please visit www.harbourbiomed.com.